Denmark tests unmanned robotic sailboat fleet with tensions high in the region
KOGE MARINA, Denmark — From a distance they look almost like ordinary sailboats, their sails emblazoned with the red-and-white flag of Denmark .
But these 10-meter (30-foot) -long vessels carry no crew and are designed for surveillance.
Four uncrewed robotic sailboats, known as 'Voyagers,' have been put into service by Denmark's armed forces for a three-month operational trial.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
A Scientist Says Humans Will Reach the Singularity Within 20 Years
"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." Here's what you'll learn when you read this story: Futurists have long debated the arrival of the singularity, when human and artificial intelligence will merge, a concept borrowed from the world of quantum physics. American computer scientist and futurist Ray Kurzweil has long argued that the singularity would likely occur around the middle of the 21st century, and with the rise of AI, his predictions are gaining more credence. In his book, The Singularity is Nearer, Kurzweil doubles down on those predictions and details how humanity's intelligence will increase a millionfold via nanobots (among other things). You don't exactly become a world-renowned futurist by making safe predictions. And while some of these past predictions haven't exactly come to pass (Back to the Future Part II, specifically), these ideas help expand our thoughts on what exactly the future might look like. And no one makes futuristic predictions quite like Ray Kurzweil. An American computer scientist-turned-futurist, Kurzweil has long believed that humanity is headed toward what's known as 'the singularity,' when man and machine merge. In 1999, Kurzweil theorized that artificial general intelligence would be achieved once humanity could achieve a technology capable of a trillion calculations per second, which he pegged to occur in 2029. Experts at the time scoffed at the idea, figuring it'd be at least a century or more, but with Kurzweil's timeline only a few years off—and talk of AGI spreading—that decades-old prediction is beginning to loom large. Get the Issue Get the Issue Get the Issue Get the Issue Get the Issue Get the Issue Get the IssueGet the Issue Get the Issue In his 2024 book, The Singularity is Nearer (a play on his 2005 book of the same name minus an 'er'), Kurzweil doubles down on these ideas in the modern era of artificial intelligence. Not only is he "sticking with [his] five years' prediction, as he said in a TED Talk, Kurzweil also believes that humans will achieve a millionfold intelligence by 2045, aided by brain interfaces formed with nanobots non-invasively inserted into our capillaries. 'We're going to be a combination of our natural intelligence and our cybernetic intelligence,' Kurzweil said in an interview with The Guardian, 'and it's all going to be rolled into one. We are going to expand intelligence a millionfold by 2045, and it is going to deepen our awareness and consciousness.'$13.99 at While this idea subscribes to a merger more akin to physical intervention to bridge the gap between man and machine, other philosophers and AI experts agree that some form of merger is likely inevitable, and in some ways, is already beginning. In July 2024, Oxford's Marcus du Sautoy and Nick Bostrom both expounded on the hopeful and harrowing possibilities of our AI future, and for both of them, a kind of synthesis appeared inevitable. 'I think that we are headed toward a hybrid future,' Sautoy told Popular Mechanics. 'We still believe that we are the only beings with a high level of consciousness. This is part of the whole Copernican journey that we are not unique. We're not at the center.' Of course, this 'Brave New World' of a hybrid AI-human existence brings with it a plethora of issues both political and personal. What will humans do for jobs? Could we possibly live forever? Would that change the very idea of what it means to be human? Kurzweil, like many other futurists, is relatively optimistic on this front. In that same interview with The Guardian, Kurzweil highlights the idea of a Universal Basic Income as a necessity rather than a fringe idea currently supported in more progressive circles, and AI will bring unprecedented advancements in medicine, meaning the very idea of immortality isn't out of the realm of possibility. 'In the early 2030s we can expect to reach longevity escape velocity where every year of life we lose through aging we get back from scientific progress,' Kurzweil told The Guardian. 'And as we move past that, we'll actually get back more years. It isn't a solid guarantee of living forever—there are still accidents—but your probability of dying won't increase year to year.' Just like Back to the Future Part II predicted flying cars, so too could these technology-fueled utopias crumble to dust as these dates inch closer and closer. But 25 years ago, Kurzweil predicted we'd be rapidly approaching a major moment in humanity's technological history at the tail end of this decade. Currently, no evidence suggests the contrary. Get the Guide Get the Guide Get the Guide Get the Guide Get the Guide You Might Also Like The Do's and Don'ts of Using Painter's Tape The Best Portable BBQ Grills for Cooking Anywhere Can a Smart Watch Prolong Your Life?
Gizmodo
an hour ago
- Gizmodo
Could Ozempic Treat Migraines, Too? Small Study Finds Early Promise for GLP-1s
Got a blinding headache? Some GLP-1 therapy could surprisingly help. A recent clinical trial has found early evidence that these popular drugs, typically used to treat obesity and type 2 diabetes, may also reduce migraine episodes. Researchers in Italy conducted the small pilot trial, which involved dozens of patients living with obesity and chronic migraine headaches. People experienced a significant drop in the number of migraine days each month upon taking liraglutide, the researchers found—even when they didn't lose weight on the drug. The results, while preliminary, indicate that GLP-1s could be a valuable add-on treatment for some people with migraines who haven't responded to other medications, the study authors say. 'Our findings show that liraglutide may be effective in the treatment of unresponsive high-frequency or chronic migraine in patients with obesity,' the researchers, based at the University of Naples Federico II, wrote in their paper, published this month in the journal Headache. A Florida Man's Migraines Turned Out to Be Literal Brainworms GLP-1s mimic a hormone important to regulating hunger and metabolism. This drug class has been around for two decades, and the latest approved iterations, semaglutide and tirzepatide, are substantially more effective at helping people lose weight and control their blood sugar than diet and exercise alone. Scientists have learned over time that the potential health benefits of GLP-1s may extend beyond weight loss alone, however. Some early studies have suggested GLP-1s can tamp down the drug-related cravings of people with substance use disorders, for instance. Chronic migraines are a complex condition, with many possible factors behind them. But one such factor is increased intracranial pressure in the head, according to the study researchers. Since past research has shown that GLP-1s can reduce this pressure, they hypothesized this drug class could be a potential migraine treatment. They tested liraglutide, an older GLP-1 drug, on 31 patients with obesity and unresponsive migraines for 12 weeks. By the study's end, people's average monthly days of migraine had dropped from around 20 days to just under 11—a nearly 50% drop. One participant even became completely free of migraines. Some people also experienced modest weight loss, but interestingly enough, their degree of weight loss wasn't correlated to the improvement in migraines they experienced. In other words, liraglutide's effect on migraines appeared to be independent of its weight loss effect. New Migraine Drug Can Even Tackle the Most Difficult Cases, Study Finds As the researchers fully acknowledge, this was just a proof-of-concept study, not meant to definitively prove anything. And there are important lingering questions left to resolve. Will newer GLP-1 drugs like semaglutide (Ozempic and Wegovy) be more effective at relieving pressure-related migraines as well, for example? But given how difficult migraines can be to remedy, even with recent drug approvals, finding a new and already tested avenue for treatment could be invaluable. More studies should validate whether intracranial pressure-reducing drugs, GLP-1s included, can be a new target for migraine relief, the researchers say. But it's a promising start.
Medscape
an hour ago
- Medscape
Revascularizing Vessels After STEMI Sees Durable Gains
For patients with ST-elevation myocardial infarction, complete revascularization of all vessels with stenosis appears to be a more effective long-term approach than targeting culprit arteries alone, according to a 10-year follow-up analysis of a Danish study. The new findings come from an analysis of patients in the DANAMI-3-PRIMULTI trial, one of several studies between 2017 and 2024 to show the value of complete revascularization, which is now recommended for patients with STEMI and multivessel disease by both US and European guidelines. But those recommendations are based on shorter-term outcomes. The question remained how long the benefits would last, said Thomas Engstrøm, MD, PhD, professor and senior consultant in the Department of Invasive Cardiology at The Heart Center, part of the University of Copenhagen, Copenhagen, Denmark. The latest data, published May 20 in the Journal of the American College of Cardiology , span the longest to date of a study of complete vs culprit-artery revascularization, he said. 'A short term of 1 or 3 years is good to see if a treatment works, but what's more important for patients is whether it is durable,' said Engstrøm, one of the authors of the original study as well as the follow-up analysis. 'Many of our patients are not that old; 10 years is not that long for a patient who has an acute myocardial infarction at 60 years of age.' The follow-up included all 627 patients in the original study, 313 of whom were randomized to culprit-artery revascularization and 314 to complete revascularization. Engstrøm said he and his colleagues manually reviewed hospital records for each patient to ensure they captured any events. Which Benefits Last? Complete revascularization was associated with better outcomes for a combination of death, recurring myocardial infarction, and recurring revascularization (hazard ratio, 0.76 compared with culprit-artery revascularization), according to the researchers. The ability of complete revascularization to prevent further revascularization accounted for the bulk of the difference, with a hazard ratio of 0.62. The results 'add further support for complete revascularization. It shows there's a persistent benefit, especially in regard to the need for repeat vascularization,' said William Fearon, MD, a professor of medicine at Stanford University, chief of interventional cardiology at Stanford University School of Medicine, Stanford, California, and the chief of the cardiology section at the VA Palo Alto Health Care System, Palo Alto, California. He was not involved in the trial. But other outcomes showed less benefit and were not statistically significant. All-cause mortality was almost the same in both groups (hazard ratio, 0.96). Cardiovascular mortality showed a 20% reduction with complete revascularization, but this difference was not statistically significant due to the low number of patients, Engstrøm said. Rates of recurrent myocardial infarction and definite stent thrombosis also were essentially the same in each group, the researchers found (odds ratio, 0.90 for both outcomes). Open Questions Other studies have shown benefit for mortality and myocardial infarction following complete revascularization. The COMPLETE trial in 2019 showed benefits for a combined outcome of cardiovascular death or myocardial infarction after 3 years (hazard ratio, 0.74), driven by a lower rate of recurrent myocardial infarction (hazard ratio, 0.68). At least two factors may explain the discrepancy in findings, Engstrøm said. The COMPLETE trial was much larger, with more than 4000 patients. 'It was more adequately powered to show effects,' Engstrøm said. 'I think the [DANAMI-3-PRIMULTI] study was relatively small relative to some others,' Fearon said. 'So, that limits the ability to look at specific endpoints that have a lower incidence.' 'What we're learning is that, for harder endpoints like [myocardial infarction], the benefit is really in more severe lesions.' DANAMI-3-PRIMULTI did not analyze patient outcomes by severity of lesions, whereas the COMPLETE trial did, he noted. In addition, revascularization was guided by different methods in the two trials. In DANAMI-3-PRIMULTI, complete revascularization was guided by fractional flow reserve (FFR) measurements, whereas the COMPLETE trial involved angiography-guided revascularization. 'The COMPLETE trial used a less stringent way of defining the lesions, by angiography. These lower-grade stenoses were not identified by FFR,' Engstrøm said. DANAMI-3-PRIMULTI did not measure FFR in patients in whom revascularization involved only the culprit artery, Fearon said. Another study reported in 2017, Compare-Acute, measured FFR in both complete and culprit-artery revascularization groups and found a lower FFR was associated with a higher rate of subsequent events, he said. The COMPLETE-2 trial currently underway is looking at whether FFR or angiography is a better way to measure blood flow in vessels, Engstrøm said. 'The COMPLETE trial showed us that angiography-guided complete revascularization is superior to culprit-artery revascularization,' said Fearon, who is on the steering committee for the COMPLETE-2 study. 'The other trials showed us that FFR-guided complete revascularization is superior, but we don't know whether FFR-guided complete revascularization is superior to angiography-guided complete revascularization.' Studies to date of complete vs culprit-vessel revascularization show 'a very uniform arrow that leads to complete revascularization,' Engstrøm said, 'but there are some corners that have not been shed light on.' Engstrøm is on the advisory board for Novo Nordisk and Abbott Medical. He has received speaker's fees from Abbott Medical, Boston Scientific, and Novo Nordisk. Fearon receives institutional research support from Abbott, CathWorks, and Medtronics. He has received consulting fees or honoraria from Shockwave Medical and from Edwards Lifesciences, and he has stock options in Heartflow.
